<DOC>
	<DOC>NCT00847990</DOC>
	<brief_summary>The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or other chromosome abnormality.</brief_summary>
	<brief_title>Non-Invasive Screening for Fetal Aneuploidy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Aneuploidy</mesh_term>
	<criteria>Subject is willing to provide written informed consent Pregnant female with singleton gestation 18 years of age or older Subject agrees to provide a 20 to 30 mL venous blood sample Subject is one of the following: A) currently scheduled to undergo an amniocentesis and/or CVS procedure, OR B) currently in the first trimester of pregnancy and planning to undergo an amniocentesis in the second trimester Subject will receive results of a genetic analysis that includes evaluation of the fetus for aneuploidy Subject lacks the capacity to provide informed consent Twins, triplets or other multiple gestation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Down syndrome</keyword>
	<keyword>aneuploidy</keyword>
	<keyword>chromosome abnormality</keyword>
	<keyword>amniocentesis</keyword>
	<keyword>chorionic villus sampling</keyword>
	<keyword>Laboratory Developed Test (LDT)</keyword>
</DOC>